0001630176 false hyex 0001630176 2022-02-10 2022-02-10 iso4217:USD xbrli:shares iso4217:USD xbrli:shares
 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Form 8-K

 

Current Report

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): February 10, 2022

 

HEALTHY EXTRACTS INC.

(Exact name of registrant as specified in its charter)

 

Nevada
(State or other
jurisdiction of incorporation)
  333-202542
(Commission
File Number)
  47-2594704
(I.R.S. Employer
Identification No.)
         
6445 S. Tenaya Way, Suite B110
Las Vegas, NV 89113
 (Address of principal executive offices)  (zip code)
         
(702) 463-1004
(Registrant’s telephone number, including area code)
         
 (Former name or former address, if changed since last report.)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

oWritten communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

oSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

oPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

oPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company o

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  o

 

 

 

 

Section 1 – Registrant’s Business and Operations

 

Item 1.01 Entry into a Material Definitive Agreement.

 

On February 10, 2022 and February 22, 2022, we entered into a Common Stock Purchase Warrant and a Promissory Note, respectively, with Bruce Kaiman. The warrants are to acquire two million (2,000,000) shares of our common stock, are exercisable for three (3) years at an exercise price of $0.05 per share, and contain a cashless exercise option for the holder. The note is in the principal amount of Two Hundred Thousand Dollars ($200,000), bears interest at a rate of ten percent (10%) per annum, and has a maturity date of February 15, 2023. Eleven (11) monthly payments of $17,804.26 are due between the issue date and the maturity date.

 

Section 3 – Securities and Trading Markets

 

 

Item 3.02Unregistered Sale of Equity Securities.

 

The disclosure in Item 1.01 above regarding the issuance of securities in the exchange is incorporated herein by reference.

 

The shares of common stock issued pursuant to the Securities Purchase Agreements were offered and sold in reliance on an exemption from registration pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended. The investors have acquired the securities for investment purposes only and not with a view to, or for sale in connection with, any distribution thereof. The securities were not issued through any general solicitation or advertisement.

 

Section 9 – Financial Statements and Exhibits.

 

Item 9.01Financial Statements and Exhibits.

 

(d)Exhibits

 

10.1 Common Stock Purchase Warrant dated February 10, 2022
   
10.2 Promissory Note dated February 22, 2022

- 2 -

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  Healthy Extracts Inc.
   
Dated: March 2, 2022  /s/ Kevin Pitts
  By:    Kevin “Duke” Pitts
  Its:     President

- 3 -

HEALTHY EXTRACTS INC.

 

THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (“THE ACT”), OR THE SECURITIES LAWS OF ANY STATE, AND MAY NOT BE OFFERED, SOLD, TRANSFERRED, PLEDGED, HYPOTHECATED OR OTHERWISE DISPOSED OF EXCEPT PURSUANT TO (i) AN EFFECTIVE REGISTRATION STATEMENT UNDER THE ACT AND ANY APPLICABLE STATE LAWS, (ii) TO THE EXTENT APPLICABLE, RULE 144 UNDER THE ACT (OR ANY SIMILAR RULE UNDER THE ACT RELATING TO THE DISPOSITION OF SECURITIES), OR (iii) AN OPINION OF COUNSEL, IF SUCH OPINION SHALL BE REASONABLY SATISFACTORY TO COUNSEL TO THE ISSUER, THAT AN EXEMPTION FROM REGISTRATION UNDER THE ACT AND APPLICABLE STATE LAW IS AVAILABLE.

 

COMMON STOCK PURCHASE WARRANT

 

THIS IS TO CERTIFY that, for value received, Bruce Kaiman (the “Holder”) is entitled, subject to the terms and conditions set forth herein, to purchase from Healthy Extracts Inc., a Nevada corporation (the “Company”) up to two million (2,000,000) fully paid and nonassessable shares of common stock of the Company (the “Warrant Securities”) at the initial price of five cents ($0.05) per share but subject to adjustment as provided in Section 4 below (the “Exercise Price”).

 

1.Exercisability.

 

(A)       General Exercisability. Subject to the vesting schedule in Section 2, below, this Warrant may be exercised between the date hereof and three (3) years thereafter, by presentation and surrender hereof to the Company of a notice of election to purchase duly executed and accompanied by payment by check or wire transfer of the Exercise Price, or election to utilize the provisions of Section 1(B).

Page 1 of 7

 

(B)       Cashless Conversion of Warrants. Notwithstanding any provisions herein to the contrary, the Holder may convert this Warrant into that number of shares of the Company’s common stock by surrender of this Warrant at the principal office of the Company together with the properly endorsed form of election to purchase in which event the Company shall issue to the holder hereof a number of shares of the Company’s common stock computed using the following formula:

 

            X = Y (A-B)

       A

 

Where X = the number of shares of the Company’s common stock to be issued to the holder hereof
   
Y = the number of shares of the Company’s common stock purchasable under the Warrant or, if only a portion of the Warrant is being exercised, the portion of the Warrant being canceled (at the date of such calculation)
   
A = the fair market value of one share of the Company’s common stock (at the date of such calculation)
   
B = the Exercise Price

 

All references herein to an “exercise” of the Warrant shall include a conversion pursuant to this Section. For the purposes of the above calculation, the Fair Market Value of one share of the Company’s common stock as of a particular date shall mean:

 

(a)       If traded on a securities exchange or the NASDAQ National Market, the Fair Market Value shall be deemed to be the closing price of the common stock of the Company on such exchange or market on the date in question. If there is no closing selling price for such common stock on the date in question, then the fair market value shall be the closing selling price on the last preceding date for which such a quotation exists;

 

(b)       If actively traded over-the-counter, the Fair Market Value shall be deemed to be the closing bid price of the common stock of the Company on the date in question. If there is no closing bid price for such common stock on the date in question, then the fair market value shall be the closing bid price on the last preceding date for which such a quotation exists;

 

(c)       If the Company’s common stock is traded on multiple platforms, the Board of Directors of the Company shall determine the primary market for such common stock; and

 

(d)       If there is no active public market, the “Fair Market Value” shall be the value thereof, as determined in good faith by the Company’s Board of Directors after taking into account such factors as the Board of Directors of the Company shall deem appropriate.

 

A stock certificate representing the appropriate number of shares of the common stock shall be delivered to the holder hereof within five (5) business days following the date of exercise.

 

2.Vesting Schedule. This Warrant shall vest immediately

Page 2 of 7

 

3.           Manner of Exercise. In case of the purchase of less than all the Warrant Securities, the Company shall cancel this Warrant upon the surrender hereof and shall execute and deliver a new warrant of like tenor for the balance of the Warrant Securities. Upon the exercise of this Warrant, the issuance of certificates for securities, properties or rights underlying this Warrant shall be made forthwith (and in any event within three (3) business days thereafter) without charge to the Holder including, without limitation, any tax that may be payable in respect of the issuance thereof: provided, however, that the Company shall not be required to pay any tax in respect of income or capital gain of the Holder.

 

If and to the extent this Warrant is exercised, in whole or in part, the Holder shall be entitled to receive a certificate or certificates representing the Warrant Securities so purchased, upon presentation and surrender to the Company of the form of election to purchase attached hereto duly executed, and accompanied by payment of the purchase price.

 

4.Adjustment in Number of Shares.

 

(A)       Adjustment for Reclassifications. In case at any time or from time to time after the issue date the holders of the Common Stock of the Company (or any shares of stock or other securities at the time receivable upon the exercise of this Warrant) shall have received, or, on or after the record date fixed for the determination of eligible stockholders, shall have become entitled to receive, without payment therefore, other or additional stock or other securities or property (including cash) by way of stock split, spin-off, reclassification, combination of shares or similar corporate rearrangement (exclusive of any stock dividend of its or any subsidiary’s capital stock), then and in each such case the Holder of this Warrant, upon the exercise hereof as provided in Section 1, shall be entitled to receive the amount of stock and other securities and property which such Holder would hold on the date of such exercise if on the issue date he had been the holder of record of the number of shares of Common Stock of the Company called for on the face of this Warrant and had thereafter, during the period from the issue date, to and including the date of such exercise, retained such shares and/or all other or additional stock and other securities and property receivable by him as aforesaid during such period, giving effect to all adjustments called for during such period. In the event of any such adjustment, the Exercise Price shall be adjusted proportionally.

 

(B)       Adjustment for Reorganization, Consolidation, Merger. In case of any reorganization of the Company (or any other corporation the stock or other securities of which are at the time receivable on the exercise of this Warrant) after the issue date, or in case, after such date, the Company (or any such other corporation) shall consolidate with or merge into another corporation or convey all or substantially all of its assets to another corporation, then and in each such case the Holder of this Warrant, upon the exercise hereof as provided in Section 1 at any time after the consummation of such reorganization, consolidation, merger or conveyance, shall be entitled to receive, in lieu of the stock or other securities or property to which such Holder would be entitled had the Holder exercised this Warrant immediately prior thereto, all subject to further adjustment as provided herein; in each such case, the terms of this Warrant shall be applicable to the shares of stock or other securities or property receivable upon the exercise of this Warrant after such consummation.

Page 3 of 7

 

5.           No Requirement to Exercise. Nothing contained in this Warrant shall be construed as requiring the Holder to exercise this Warrant prior to or in connection with the effectiveness of a registration statement.

 

6.           No Stockholder Rights. Unless and until this Warrant is exercised, this Warrant shall not entitle the Holder hereof to any voting rights or other rights as a stockholder of the Company, or to any other rights whatsoever except the rights herein expressed, and, no dividends shall be payable or accrue in respect of this Warrant.

 

7.           Piggyback Registration Rights. If the Company, at any time, proposes to conduct an offering of its securities so as to register any of its securities under the Securities Act of 1933 (the “Act”), including under an S-1 Registration Statement or otherwise, the Company will at such time give written notice to the Holder of its intention so to do. If the offering being registered includes an underwriter, then subject to the approval of the underwriters, and upon the written request of the Holder, given within 10 days after receipt of any such notice, the Company will use its best efforts to cause the common stock underlying the exercise of the Warrants to be registered under the Act (with the securities which we are proposing to register).

 

8.           Exchange. This Warrant is exchangeable upon the surrender hereof by the Holder to the Company for new warrants of like tenor representing in the aggregate the right to purchase the number of Warrant Securities purchasable hereunder, each of such new warrants to represent the right to purchase such number of Warrant Securities as shall be designated by the Holder at the time of such surrender.

 

Upon receipt by the Company of evidence reasonably satisfactory to it of the loss, theft, destruction or mutilation of this Warrant, and, in case of loss, theft or destruction, of indemnity or security reasonably satisfactory to it and reimbursement to the company of all reasonable expenses incidental thereto, and upon surrender and cancellation hereof, if mutilated, the Company will make and deliver a new warrant of like tenor and amount, in lieu hereof.

 

9.           Elimination of Fractional Interests. The Company shall not be required to issue certificates representing fractions of securities upon the exercise of this Warrant, nor shall it be required to issue scrip or pay cash in lieu of fractional interests. All fractional interests shall be eliminated by rounding any fraction up to the nearest whole number of securities, properties or rights receivable upon exercise of this Warrant.

 

10.         Reservation of Securities. The Company shall at all times reserve and keep available out of its authorized shares of Common Stock or other securities, solely for the purpose of issuance upon the exercise of this Warrant, such number of shares of Common Stock or other securities, properties or rights as shall be issuable upon the exercise hereof. The Company covenants and agrees that, upon exercise of this Warrant and payment of the Principal Value, all shares of Common Stock and other securities issuable upon such exercise shall be duly and validly issued, fully paid, non-assessable and not subject to the preemptive rights of any stockholder.

Page 4 of 7

 

11.           Notices to Holder. If at any time prior to the expiration of this Warrant or its exercise, any of the following events shall occur:

 

(a)       the Company shall take a record of the holders of any class of its securities for the purpose of entitling them to receive a dividend or distribution payable otherwise than in cash, or a cash dividend or distribution payable otherwise than out of current or retained earnings, as indicated by the accounting treatment of such dividend or distribution on the books of the Company; or

 

(b)       the Company shall offer to all the holders of a class of its securities any additional shares of capital stock of the Company or securities convertible into or exchangeable for shares of capital stock of the Company, or any option or warrant to subscribe therefor; or

 

(c)       a dissolution, liquidation or winding up of the Company (other than in connection with a consolidation or merger) or a sale of all or substantially all of its property, assets and business as an entirety shall be proposed.

 

then, in any one or more said events, the Company shall give written notice of such event to the Holder at least fifteen (15) days prior to the date fixed as a record date or the date of closing the transfer books for the determination of the stockholder entitled to such dividend, distribution, convertible or exchangeable securities or subscription rights, or entitled to vote on such proposed dissolution, liquidation, winding up or sale. Such notice shall specify such record date or the date of closing the transfer books, as the case may be.

 

12.           Transferability. This Warrant may not be transferred or assigned by the Holder without prior approval by the Company, which the Company may withhold in its sole discretion, except for a Permitted Transfer. A “Permitted Transfer” means a transfer to the Holder’s member and such member’s family members or a trust their benefit upon the death of the Holder’s member or for estate planning purposes of the Holder’s member.

 

13.           Informational Requirements. The Company will transmit to the Holder such information, documents and reports as are generally distributed to stockholders of the Company concurrently with the distribution thereof to such stockholders.

 

14.           Notice. Notices to be given to the Company or the Holder shall be deemed to have been sufficiently given if delivered personally or sent by overnight courier or messenger, or by facsimile transmission. Notices shall be deemed to have been received on the date of personal delivery or facsimile transmission. The address of the Company and of the Holder shall be as set forth in the Company’s books and records.

Page 5 of 7

 

15.           Choice of Law and Venue. This Warrant and the rights of the parties hereunder shall be governed by and construed in accordance with the laws of the State of Nevada including all matters of construction, validity, performance, and enforcement and without giving effect to the principles of conflict of laws. Any action brought by any party hereto shall be brought within the State of Nevada, County of Clark.

 

16.           Successors. All the covenants and provisions of this Warrant shall be binding upon and inure to the benefit of the Company, the Holder and their respective legal representatives, successors and assigns.

 

17.           Attorneys’ Fees. Except as otherwise provided herein, if a dispute should arise between the parties including, but not limited to arbitration, the prevailing party shall be reimbursed by the non-prevailing party for all reasonable expenses incurred in resolving such dispute, including reasonable attorneys’ fees.

 

[remainder of page intentionally left blank, signature page to follow]

Page 6 of 7

 

IN WITNESS WHEREOF, the Company has caused this Warrant to be executed by the signature of its President and to be delivered in Las Vegas, Nevada.

 

Dated: February 10th, 2022

Healthy Extracts Inc.,

a Nevada corporation

 

/s/ Kevin Pitts

  By:   Kevin Pitts
  Its:   Chief Executive Officer

Page 7 of 7

 

[FORM OF ELECTION TO PURCHASE]

 

Date: ______________

 

HEALTHY EXTRACTS INC.

Attn:     President

 

Ladies and Gentlemen:

 

o The undersigned hereby elects to exercise the warrant issued to it by Healthy Extracts Inc. (the “Company”) pursuant to the Common Stock Purchase Warrant Agreement between the Company and ___________, dated ___________ (the “Warrant Agreement”) and to purchase thereunder _________ (_____) shares of Common Stock of the Company (the “Shares”) at a purchase price of five cents ($0.05) per share or an aggregate purchase price of __________ Dollars ($_____) (the “Purchase Price”).

 

o The undersigned hereby elects under the provision set forth in Section 1(B) of the Warrant Agreement to make a net exercise of the Warrant as to ___________ shares.

 

Pursuant to the terms of the Warrant Agreement the undersigned has delivered the aggregate Purchase Price herewith in full in cash or by certified check or wire transfer, if applicable.

 

The certificate(s) or other instruments for such shares shall be issued in the name of the undersigned or as otherwise indicated below.

 

  Signature:  
  [name]  
  [address]  
     
     
     

 

PROMISSORY NOTE

 

$200,000.00 February 22th, 2022

 

FOR VALUE RECEIVED, HEALTHY EXTRACTS INC., a Nevada corporation (hereinafter called the “Borrower” or the “Company”) (Trading Symbol: HYEX), hereby promises to pay to the order of Bruce Kaiman, or registered assigns (the “Holder”), in the form of lawful money of the United States of America, the principal sum of $200,000.00, which amount is the $180,000.00 actual amount of the purchase price (the “Consideration”) hereof plus an original issue discount in the amount of $20,000.00 (the “OID”)(the “Principal Amount”) and to pay interest on the unpaid Principal Amount hereof at the rate of ten percent (10%) (the “Interest Rate”) per annum. Payments under this Promissory Note (this “Note”) shall be paid in US Dollars to Lender Bruce Kaiman, 1993 Long Pointe Dr Bloomfield Hills, MI 48302, or at such place as Lender may from time to time designate in writing.

 

1.Payments. Borrower shall make payments as follows:

 

(i)       an initial payment of $17,804.26 due on April 22th, 2022;

 

(ii)       ten (10) monthly payments of $17,804.26 due on the 22nd day of each following month, beginning on May 22th, 2022 through Feb 15th, 2023; and

 

(iii)       a final payment due on March 22th, 2023 in the amount of $17,804.26.

 

(iv)       Prepayments. Borrower may pay the outstanding principal balance or a portion thereof without penalty upon any Monthly Payment.

 

b.         Application of Payments Towards Obligations. Payments received shall be first applied to accrued but unpaid interest.

 

c.         Late Payments. If payments are received after the Payment Date, there shall be a late fee of the greater of $500 or 1% of the amount of the late payment, plus accrued and unpaid interest.

 

2.       Event of Default; Accelerated Maturity Date. Upon written notice to Borrower following an Event of Default, Lender may accelerate the Maturity Date to the date of the original written notice of such default or breach or such later date specified by Lender. For purposes of this Note, an “Event of Default” shall have occurred if Borrower is in default on account of the late payment of any payment due hereunder, or has breached any other term of this Note, and such default or breach has not been cured within ten (10) days written notice of such default or breach; (b) Borrower commences a voluntary proceeding seeking liquidation, reorganization, or other relief with respect to itself or its debts under any bankruptcy, insolvency, or other similar law now or hereafter in effect or seeking the appointment of a trustee, receiver, liquidator, custodian, or other similar official of it or a substantial part of its Property or consents to any such relief or to the appointment of or taking possession by any such official in an involuntary case or other proceeding commenced against it or make a general assignment for the benefit of creditors or generally fail to pay its debts as they become due or shall take any corporate action to authorize any of the foregoing; (c) an involuntary proceeding is commenced against Borrower seeking liquidation, reorganization, or other relief with respect to it or its debts under any bankruptcy, insolvency, or other similar law now or hereafter in effect or seeking the appointment of a trustee, receiver, liquidator, custodian, or other similar official for it or a substantial part of its Property, and such involuntary proceeding shall remain undismissed and unstayed for a period of 30 consecutive days; or (d) any dissolution, liquidation or winding up of Borrower or any substantial portion of its business.

Page 1 of 3

 

3.       Default Interest. During the period that any Event of Default exists, including without limitation the nonpayment of any monthly or final amount due, the interest rate hereon shall increase to sixteen percent (16%) per annum (the “Default Rate”) and shall apply to all unpaid principle interest and fees compounded quarterly (on each Interest Payment Date) as if they were additional principal.

 

4.       Waivers. Borrower and all others who may become liable for the payment of all or any part of the obligations under this Note do hereby severally waive presentment for payment, protest and demand, notice of protest, demand and dishonor, and nonpayment of this Note and expressly agree that the maturity of this Note or any payment hereunder may be extended from time to time, at the option of the holder hereof, without in any way affecting the liability of each. Any such extension may be made without notice to any of the parties and without discharging their liability.

 

5.       Collection and Enforcement Costs. Borrower agrees to pay all costs incurred in collection and/or enforcement of this Note or any part thereof or otherwise in connection herewith, including, but not limited to, reasonable attorneys’ fees, and, in the event of court action, all costs and such additional sums and attorneys’ fees as the court may adjudge reasonable.

 

6.       Severability. If any term, provision, covenant or condition of this Note, or any application thereof, should be held by a court of competent jurisdiction to be invalid, void, or unenforceable, all provisions, covenants and conditions of this Note and all applications thereof not held invalid, void or unenforceable, shall continue in full force and effect and shall in no way be affected, impaired or invalidated thereby.

 

7.       Assignability. This Note shall be binding upon the Borrower and its successors and assigns, and shall inure to the benefit of Lender and Lender’s successor and assigns. This Note may be assigned by Lender upon written notice to (and without the consent of) Borrower, provided that each transferee of this Note must be an “accredited investor” (as defined in Rule 501(a) of Regulation D under the Securities Act of 1933, as amended).

Page 2 of 3

 

8.       Governing Law; Jurisdiction. The laws of the State of Nevada shall govern the va- lidity, construction, performance and effect of this Note. Except as otherwise required by applicable law, Borrower and Lender each hereby irrevocably: (a) submits in any legal proceeding relating to this Note to the exclusive jurisdiction of any state or United States court of competent jurisdiction sitting in the State of Nevada and agrees to suit being brought in such courts, as Lender may elect; and (b) waives any objection it may now or hereafter have to the venue of such proceeding in any such court or that such proceeding was brought in an inconvenient forum.

 

IN WITNESS WHEREOF, Borrower has caused this Note to be duly executed and delivered on the date first above written.

 

  Healthy Extracts Inc.
     
  By:  /s/ Kevin Pitts
  Name: Kevin Pitts
  Title: Chief Executive Officer

Page 3 of 3